methyl 3-(4-(methylsulfanyl)phenyl)-2-oxopropanoate | 737823-70-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-(4-(methylsulfanyl)phenyl)-2-oxopropanoate
• 英文别名: methyl 3-(4-methylsulfanylphenyl)-2-oxopropanoate
• CAS: 737823-70-0
• 化学式: C₁₁H₁₂O₃S
• 分子量: 224.28
• InChiKey: FZXSYWHEZHMWPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  68.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3-(4-(methylsulfanyl)phenyl)-2-oxopropanoate 在 吡啶 、 manganese(IV) oxide 、 Oxone 、 lithium aluminium tetrahydride 、 pyridinium hydrobromide perbromide 、 palladium 10% on activated carbon 、 potassium tert-butylate 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 氯仿 、 水 、 N,N-二甲基甲酰胺 为溶剂， 50.0 ℃ 、303.99 kPa 条件下， 反应 32.0h， 生成 di-tert-butyl {[(4-{2-[2-(acetylamino)-5-(4-(methylsulfonyl)phenyl)-1,3-thiazol-4-yl]ethyl}phenyl)amino]-methylidene}biscarbamate
  参考文献：
  名称：

  Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: Part 2

  摘要：

  Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although our previous compound 1 showed potent VAP-1 inhibitory activity, the activity differed between humans and rats. This issue was overcome by a hybrid design using human VAP-1 specific inhibitor 2, which was found by high-throughput screening (HTS), a docking study of a human VAP-1 homology model, and an analysis of sequence information for humans and rats. As a result, we identified compound 35c, which showed strong VAP-1 inhibitory activity (human IC50 of 20 nM; rat IC50 of 72 nM) and significant inhibitory effects in the ex vivo test. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.02.048
• 作为产物：
  描述：

  4-(甲基巯基)苯甲醛 在 盐酸 、 sodium acetate 、 乙酸酐 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.5h， 生成 methyl 3-(4-(methylsulfanyl)phenyl)-2-oxopropanoate
  参考文献：
  名称：

  Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: Part 2

  摘要：

  Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although our previous compound 1 showed potent VAP-1 inhibitory activity, the activity differed between humans and rats. This issue was overcome by a hybrid design using human VAP-1 specific inhibitor 2, which was found by high-throughput screening (HTS), a docking study of a human VAP-1 homology model, and an analysis of sequence information for humans and rats. As a result, we identified compound 35c, which showed strong VAP-1 inhibitory activity (human IC50 of 20 nM; rat IC50 of 72 nM) and significant inhibitory effects in the ex vivo test. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.02.048

文献信息

• [EN] THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS<br/>[FR] DERIVES DE THIAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE VAP-1
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004067521A1

  公开（公告）日：2004-08-12

  A compound of the formula (I): R1-NH-X-Y-Z (I) wherein R1 is acyl; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond, lower alkylene or -COHN-; and Z is a groupe of the formulae (II) or (III) wherein R2 is a specified substituent or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor for preventing or treating a VAP-1associated disease, especially macular edema.

  一种化合物的分子式（I）：R1-NH-X-Y-Z（I），其中R1为酰基；X为可选取代噻唑衍生的双价残基；Y为键，较低的烷基或-COHN-；Z为分子式（II）或（III）中的基团，其中R2为特定的取代基或其药用可接受的盐，用作预防或治疗与血管粘附蛋白-1（VAP-1）相关的疾病的VAP-1抑制剂，特别是黄斑水肿。
• Thiazole derivatives
  申请人：Inoue Takayuki

  公开号：US20060128770A1

  公开（公告）日：2006-06-15

  A compound of the formula (I): R 1 —NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

  化合物公式(I): R1—NH—X—Y-Z (I)，其中每个符号如规范所定义，或其药学上可接受的盐，可用作血管黏附蛋白-1（VAP-1）抑制剂，制备一种制药组合物，一种预防或治疗VAP-1相关疾病（尤其是黄斑水肿）的方法，该方法包括向哺乳动物投与化合物或其药学上可接受的盐的有效量等。
• Method for treating vascular hyperpermeable disease
  申请人：Ueno Ryuji

  公开号：US20060229346A1

  公开（公告）日：2006-10-12

  The present invention provides a method for treating a vascular hyperpermeable disease (except macular edema), which method comprises administering to a patient in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. The agents are 2-acylamino thiazole compounds.

  本发明提供了一种治疗血管过渗性疾病（除黄斑水肿外）的方法，该方法包括向需要治疗该疾病的患者施用足量的血管粘附蛋白-1（VAP-1）抑制剂。该抑制剂为2-酰胺基噻唑类化合物。
• METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE
  申请人：UENO Ryuji

  公开号：US20080119462A1

  公开（公告）日：2008-05-22

  The present invention provides a method for treating a vascular hyperpermeable disease (except macular edema), which method comprises administering to a patient in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease.

  本发明提供了一种治疗血管过渗性疾病（除了黄斑水肿）的方法，该方法包括向需要治疗该疾病的患者施用足够治疗该疾病的血管粘附蛋白-1（VAP-1）抑制剂。
• THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS
  申请人：Astellas Pharma Inc.

  公开号：EP1587800A1

  公开（公告）日：2005-10-26